Katherine Cocca Atkinson - 31 May 2022 Form 3 Insider Report for Evofem Biosciences, Inc. (EVFM)

Role: Chief Commercial Officer
Signature: /s/ Justin J. File
Issuer symbol: EVFM
Transactions as of: 31 May 2022
Net transactions value: $0
Form type: 3
Filing time: 07 Jun 2022, 08:45:37 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	EVFM	Common Stock						16,667	31 May 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EVFM	Stock option (right to buy)							31 May 2022	Common Stock	4,000	$6.27	Direct	F2
holding	EVFM	Stock option (right to buy)							31 May 2022	Common Stock	6,667	$7.34	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022.
F2	The shares of common stock exercisable pursuant to the option will vest as follows: 25% will vest after the first year year of service for the Issuer measured from November 22, 2021, 75% will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from November 22, 2022.
F3	The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022.